Q5112 Injection ontruzant 10 milligrams
Also known as: Ontruzant injection, trastuzumab-dkst, anti-HER2
Injection of Ontruzant, trastuzumab-dkst biosimilar per 10 milligrams, a human epidermal growth factor receptor 2 antagonist.
In Plain Language
breast cancer fighting drug; targeted cancer therapy
Clinical Context
Used for HER2-positive breast cancer and gastric cancer treatment to inhibit tumor growth.
RVU Information
CPT Q5112 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5112?
CPT Q5112 (Injection ontruzant 10 milligrams) is a Q Codes code. Injection of Ontruzant, trastuzumab-dkst biosimilar per 10 milligrams, a human epidermal growth factor receptor 2 antagonist.
Is Q5112 covered by insurance?
Q5112 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for HER2-positive breast cancer and gastric cancer treatment to inhibit tumor growth.
When is CPT Q5112 used?
Used for HER2-positive breast cancer and gastric cancer treatment to inhibit tumor growth.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.